Income statement
USD
Annual
| Metric | 2024 | 2022 | 2021 | 2020 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 534 | 9K | 0 |
| Gross Profit | -24K | 0 | 334 | 2K | 0 |
| Operating Income | -83K | -1M | -2M | -170K | -3M |
| EBITDA | -59K | -1M | -2M | -168K | -136K |
| Net Income | -183K | -2M | -4M | -349K | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-98.57%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 98.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC -23.0%. Stock Foundry combines RTSL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RTSL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RTSL Max Drawdown
-98.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RTSL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$2.6M
-631.8% YoY
Free Cash Flow
-$21.8K
+87.0% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2022 | 2021 | 2020 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 534 | 9K | 0 |
| Gross Profit | -24K | 0 | 334 | 2K | 0 |
| Operating Income | -83K | -1M | -2M | -170K | -3M |
| EBITDA | -59K | -1M | -2M | -168K | -136K |
| Net Income | -183K | -2M | -4M | -349K | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2022 | 2021 | 2020 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 192K | 136K | 12K |
| Total Assets | 968K | 2M | 2M | 445K | 26K |
| Total Liabilities | 4M | 5M | 4M | 2M | 3M |
| Shareholder Equity | -3M | -3M | -1M | -1M | -3M |
| Total Debt | 3M | 4M | 2M | 1M | 3M |
| Net Debt | 3M | 4M | 2M | 1M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22K
+83.2% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
22K
+87.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
5.9%
Debt / Equity
-1.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.